215 related articles for article (PubMed ID: 30936376)
21. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
Behling J; Kaes J; Münzel T; Grabbe S; Loquai C
Melanoma Res; 2017 Apr; 27(2):155-158. PubMed ID: 27977496
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
Civardi G; Medioli A; Braghieri C; Ambroggi M; Immovilli P; Orsucci S; Contini P; Aronica G; Cavanna L
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792910
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
24. Vision loss with pembrolizumab treatment: A report of two cases.
Telfah M; Whittaker TJ; C Doolittle G
J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
[TBL] [Abstract][Full Text] [Related]
25. BASHH UK guideline for the management of epididymo-orchitis, 2010.
Street E; Joyce A; Wilson J;
Int J STD AIDS; 2011 Jul; 22(7):361-5. PubMed ID: 21729951
[TBL] [Abstract][Full Text] [Related]
26. Fine needle aspiration cytology of tubercular epididymitis and epididymo-orchitis.
Sah SP; Bhadani PP; Regmi R; Tewari A; Raj GA
Acta Cytol; 2006; 50(3):243-9. PubMed ID: 16780016
[TBL] [Abstract][Full Text] [Related]
27. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
Akturk HK; Alkanani A; Zhao Z; Yu L; Michels AW
J Clin Endocrinol Metab; 2018 Oct; 103(10):3589-3592. PubMed ID: 30124874
[TBL] [Abstract][Full Text] [Related]
28. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
29. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
30. Sonographic findings in tuberculous epididymitis and epididymo-orchitis.
Chung JJ; Kim MJ; Lee T; Yoo HS; Lee JT
J Clin Ultrasound; 1997 Sep; 25(7):390-4. PubMed ID: 9282805
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
33. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
Kapadia RK; Ney DE; Hannan M; Farley M; Pastula DM; Piquet AL
J Neuroimmunol; 2020 Jul; 344():577259. PubMed ID: 32416558
[TBL] [Abstract][Full Text] [Related]
34. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
35. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
36. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Suliman AM; Bek SA; Elkhatim MS; Husain AA; Mismar AY; Eldean MZS; Lengyel Z; Elazzazy S; Rasul KI; Omar NE
Cancer Immunol Immunother; 2021 Apr; 70(4):935-944. PubMed ID: 33070259
[TBL] [Abstract][Full Text] [Related]
37. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
38. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
Gunjur A; Klein O; Kee D; Cebon J
J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
[TBL] [Abstract][Full Text] [Related]
39. Preoperative diagnosis of bilateral tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guerin therapy for superficial bladder carcinoma.
Muttarak M; Lojanapiwat B; Chaiwun B; Wudhikarn S
Australas Radiol; 2002 Jun; 46(2):183-5. PubMed ID: 12060159
[TBL] [Abstract][Full Text] [Related]
40.
Farouji A; Haddad AW; Khan NY; Battah A; Ahmad AS; Slim J
Eur J Case Rep Intern Med; 2024; 11(1):004205. PubMed ID: 38223271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]